378 related articles for article (PubMed ID: 26199870)
1. The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment - Beyond classical regression.
Teipel SJ; Kurth J; Krause B; Grothe MJ;
Neuroimage Clin; 2015; 8():583-93. PubMed ID: 26199870
[TBL] [Abstract][Full Text] [Related]
2. Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.
Xu L; Wu X; Li R; Chen K; Long Z; Zhang J; Guo X; Yao L;
J Alzheimers Dis; 2016; 51(4):1045-56. PubMed ID: 26923024
[TBL] [Abstract][Full Text] [Related]
3. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
4. Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease.
Ota K; Oishi N; Ito K; Fukuyama H; ;
J Neurosci Methods; 2015 Dec; 256():168-83. PubMed ID: 26318777
[TBL] [Abstract][Full Text] [Related]
5. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
[TBL] [Abstract][Full Text] [Related]
6. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
[TBL] [Abstract][Full Text] [Related]
7. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
[TBL] [Abstract][Full Text] [Related]
8. Longer-Term Investigation of the Value of 18F-FDG-PET and Magnetic Resonance Imaging for Predicting the Conversion of Mild Cognitive Impairment to Alzheimer's Disease: A Multicenter Study.
Inui Y; Ito K; Kato T;
J Alzheimers Dis; 2017; 60(3):877-887. PubMed ID: 28922157
[TBL] [Abstract][Full Text] [Related]
9. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset.
Altomare D; Ferrari C; Caroli A; Galluzzi S; Prestia A; van der Flier WM; Ossenkoppele R; Van Berckel B; Barkhof F; Teunissen CE; Wall A; Carter SF; Schöll M; Choo ILH; Grimmer T; Redolfi A; Nordberg A; Scheltens P; Drzezga A; Frisoni GB;
J Neurol; 2019 Oct; 266(10):2535-2545. PubMed ID: 31267207
[TBL] [Abstract][Full Text] [Related]
11. Prognosis of conversion of mild cognitive impairment to Alzheimer's dementia by voxel-wise Cox regression based on FDG PET data.
Sörensen A; Blazhenets G; Rücker G; Schiller F; Meyer PT; Frings L;
Neuroimage Clin; 2019; 21():101637. PubMed ID: 30553760
[TBL] [Abstract][Full Text] [Related]
12. Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.
Yu P; Dean RA; Hall SD; Qi Y; Sethuraman G; Willis BA; Siemers ER; Martenyi F; Tauscher JT; Schwarz AJ
J Alzheimers Dis; 2012; 32(2):373-85. PubMed ID: 22796873
[TBL] [Abstract][Full Text] [Related]
13. Multimodal Classification of Mild Cognitive Impairment Based on Partial Least Squares.
Wang P; Chen K; Yao L; Hu B; Wu X; Zhang J; Ye Q; Guo X;
J Alzheimers Dis; 2016 Aug; 54(1):359-71. PubMed ID: 27567818
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
[TBL] [Abstract][Full Text] [Related]
15. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
[TBL] [Abstract][Full Text] [Related]
16. Improved Risk Stratification for Progression from Mild Cognitive Impairment to Alzheimer's Disease with a Multi-Analytical Evaluation of Amyloid-β Positron Emission Tomography.
Beyer L; Brendel M; Scheiwein F; Sauerbeck J; Hosakawa C; Alberts I; Shi K; Bartenstein P; Ishii K; Seibyl J; Cumming P; Rominger A;
J Alzheimers Dis; 2020; 74(1):101-112. PubMed ID: 31985461
[TBL] [Abstract][Full Text] [Related]
17. Prediction of Alzheimer's Disease in Amnestic Mild Cognitive Impairment Subtypes: Stratification Based on Imaging Biomarkers.
Ota K; Oishi N; Ito K; Fukuyama H; ;
J Alzheimers Dis; 2016 Apr; 52(4):1385-401. PubMed ID: 27079727
[TBL] [Abstract][Full Text] [Related]
18. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
Tosun D; Schuff N; Jagust W; Weiner MW;
Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
[TBL] [Abstract][Full Text] [Related]
19. Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.
Dukart J; Sambataro F; Bertolino A
J Alzheimers Dis; 2016; 49(4):1143-59. PubMed ID: 26599054
[TBL] [Abstract][Full Text] [Related]
20. Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients.
Choo IH; Ni R; Schöll M; Wall A; Almkvist O; Nordberg A
J Alzheimers Dis; 2013; 33(4):929-39. PubMed ID: 23047371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
